Evidence map›Paper›PMID 30546937›Full record

ArticleOncoimmunology

Identification and editing of stem-like cells in methylcholanthrene-induced sarcomas.

Emilie T E Gross, Carlos D Peinado, Yujin Jung, Semi Han, Beichen Liu, Endi K Santosa, Jack D Bui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Immune evasion by cancer stem cells.Regenerative therapy · 2021
    Review
  5. Emerging trends in immunotherapy for pediatric sarcomas.Journal of hematology & oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emilie T E GrossDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Carlos D PeinadoDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Yujin JungDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Semi HanDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Beichen LiuDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Endi K SantosaDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.
Jack D BuiDepartment of Pathology, University of California San Diego, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cancer stem cell (CSC) paradigm posits that specific cells within a tumor, so-called CSC-like cells, have differing levels of tumorigenicity and chemoresistance. Original studies of CSCs identified them in human cancers and utilized mouse xenograft models to define the cancer initiating properties of these cells, thereby hampering the understanding of how immunity could affect CSCs. Indeed, few studies have characterized CSCs in the context of cancer immunoediting, and it is currently not clear how immunity could impact on the levels or stem-like behavior of CSCs. Using the well-studied 3'methylcholanthrene (MCA) model of primary sarcoma formation, we have defined a CSC-like population within MCA-induced sarcomas as expressing high levels of stem cell antigen-1 (Sca-1) and low levels of CD90. These Sca-1

Indexed as

cancer immune surveillancecancer immunoeditingcancer stem cellsimmune therapyMCA Sarcoma

Identifiers

PMID30546937
PMCPMC6287773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.